Literature DB >> 9344347

Blood-borne signals that induce anterior chamber-associated immune deviation after intracameral injection of antigen.

J W Streilein1, S Okamoto, Y Hara, M Kosiewicz, B Ksander.   

Abstract

PURPOSE: Anterior chamber-associated immune deviation (ACAID) is elicited by an antigen-specific signal that escapes the antigen-containing eye and travels through the blood to the spleen. Two types of ACAID-inducing signals have been described: those associated with blood-borne monocytes, and a soluble factor found in serum. The authors sought to understand the basis for the existence of two distinct types of ACAID-inducing signals.
METHODS: Different kinds of antigens (soluble, cell associated, particulate) were injected into the anterior chamber (AC) of normal, presensitized, and immunodeficient mice. In addition, peritoneal exudate cells were pulsed in vitro with different kinds of antigen in the presence of transforming growth factor beta and then evaluated for the ability to induce ACAID in naive (nonsensitized) as well as T- and B-cell-deficient recipients.
RESULTS: Among antigens injected into the AC, inert particulate antigens could not induce ACAID, but soluble and cell-associated (minor histocompatibility) antigens generated cell-associated ACAID-inducing signals. In contrast, antigens injected into the AC of presensitized mice generated ACAID-inducing signals that were soluble and located in the plasma fraction of blood. All ACAID-inducing signals created in vitro with soluble, particulate, or cell-associated antigens induced ACAID in vivo.
CONCLUSIONS: Cell-associated ACAID-inducing signals are generated in naive mice regardless of the kind of antigen, and these signals arise from mobile intraocular antigen-presenting cells. However, when antigen is injected into the AC of presensitized mice, a soluble signal emerges, perhaps derived from T cells that enter the antigen-containing eye. Together, these signals dictate that subsequent exposures to ocular antigen will not evoke immunogenic inflammation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9344347

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation.

Authors:  Koh-Hei Sonoda; Taiji Sakamoto; Hong Qiao; Toshio Hisatomi; Toru Oshima; Chikako Tsutsumi-Miyahara; Mark Exley; Steven P Balk; Masaru Taniguchi; Tatsuro Ishibashi
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

3.  Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID).

Authors:  T J D'Orazio; J Y Niederkorn
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

4.  Evidence for multiple CD95-CD95 ligand interactions in anteriorchamber-associated immune deviation induced by soluble protein antigen.

Authors:  T Kezuka; J W Streilein
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

Review 5.  Resolution of uveitis.

Authors:  Gerhild Wildner; Maria Diedrichs-Möhring
Journal:  Semin Immunopathol       Date:  2019-10-07       Impact factor: 9.623

6.  CD25+, interleukin-10-producing CD4+ T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye.

Authors:  Molly E Skelsey; Elizabeth Mayhew; Jerry Y Niederkorn
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

7.  The Induction of Circulating, ACAID-Inducing Monocytes Requires CCR2/CCL2-Dependent Migration of Circulating F4/80(+) Cells into the Anterior Chamber.

Authors:  Robert E Cone; Subhasis Chattopadhyay; Roshan Pais; Sourojit Bhowmick; Roshanak Sharafieh; Yen Lemire; James O'Rourke
Journal:  Ophthalmol Eye Dis       Date:  2010-11-11

8.  Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.

Authors:  Qiuhong Li; Rehae Miller; Ping-Yang Han; Jijing Pang; Astra Dinculescu; Vince Chiodo; William W Hauswirth
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.